—

Guardant Health Inc (GH) — the peer cohort

As of 2026-10-13 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Guardant Health Inc ranks 10 of 10 in its cohort on the Closelooknet composite (43/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
GH Guardant Health Inc 43 76 17 10 info 15.2%
MEDP Medpace Holdings Inc 63 83 74 28 ok 10%
IDXX IDEXX Laboratories Inc 55 25 85 24 bear 32%
ILMN Illumina Inc 55 92 76 20 bull 10.6%
ICLR ICON PLC 45 66 32 51 info 19.4%
NTRA Natera Inc 44 92 23 6 bull 9.1%
HALO Halozyme Therapeutics Inc 74 93 94 48 ok 6.2%
DXCM DexCom Inc 66 85 80 35 bull 7.2%
ONC BeiGene, Ltd. 63 75 62 30 info 9.4%
ARGX argenx NV ADR 62 47 74 29 info 25.2%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-13

Quick answers

Who are Guardant Health Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Medpace Holdings Inc (MEDP), IDEXX Laboratories Inc (IDXX), Illumina Inc (ILMN), ICON PLC (ICLR), Natera Inc (NTRA), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM), BeiGene, Ltd. (ONC) and others.

How does GH score against its peers?

Guardant Health Inc's composite reads 43/100, ranking 10 of 10 in its cohort as of 2026-10-13; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.